AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a research report issued to clients and investors on Friday.
A number of other research analysts also recently commented on AZN. Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Thursday, September 21st. Sanford C. Bernstein set a GBX 5,780 ($78.38) price target on AstraZeneca and gave the company a “buy” rating in a research note on Monday, September 25th. Barclays reaffirmed an “overweight” rating and issued a GBX 6,300 ($85.44) price target on shares of AstraZeneca in a research note on Monday, September 25th. BNP Paribas set a GBX 5,800 ($78.65) price target on AstraZeneca and gave the company a “buy” rating in a research note on Monday, September 25th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a GBX 5,600 ($75.94) price target on shares of AstraZeneca in a research note on Thursday, October 5th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca has a consensus rating of “Hold” and an average target price of GBX 5,219 ($70.78).
AstraZeneca (AZN) traded up GBX 62.50 ($0.85) during mid-day trading on Friday, reaching GBX 5,043 ($68.39). The company had a trading volume of 3,019,909 shares, compared to its average volume of 1,610,000. The firm has a market capitalization of $63,860.00 and a P/E ratio of 2,508.96. AstraZeneca has a fifty-two week low of GBX 4,136.50 ($56.10) and a fifty-two week high of GBX 5,520 ($74.86).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.